CLLS
Price
$1.20
Change
-$0.06 (-4.76%)
Updated
Apr 3 closing price
Capitalization
168.42M
33 days until earnings call
TGTX
Price
$37.75
Change
-$1.59 (-4.04%)
Updated
Apr 4, 11:26 AM (EDT)
Capitalization
6.18B
32 days until earnings call
Ad is loading...

CLLS vs TGTX

Header iconCLLS vs TGTX Comparison
Open Charts CLLS vs TGTXBanner chart's image
Cellectis SA
Price$1.20
Change-$0.06 (-4.76%)
Volume$108.23K
Capitalization168.42M
TG Therapeutics
Price$37.75
Change-$1.59 (-4.04%)
Volume$9.72K
Capitalization6.18B
CLLS vs TGTX Comparison Chart
Loading...
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLLS vs. TGTX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and TGTX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CLLS: $1.20 vs. TGTX: $39.34)
Brand notoriety: CLLS and TGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLLS: 26% vs. TGTX: 93%
Market capitalization -- CLLS: $168.42M vs. TGTX: $6.18B
CLLS [@Biotechnology] is valued at $168.42M. TGTX’s [@Biotechnology] market capitalization is $6.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLLS’s FA Score shows that 1 FA rating(s) are green whileTGTX’s FA Score has 1 green FA rating(s).

  • CLLS’s FA Score: 1 green, 4 red.
  • TGTX’s FA Score: 1 green, 4 red.
According to our system of comparison, TGTX is a better buy in the long-term than CLLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLLS’s TA Score shows that 4 TA indicator(s) are bullish while TGTX’s TA Score has 5 bullish TA indicator(s).

  • CLLS’s TA Score: 4 bullish, 3 bearish.
  • TGTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CLLS is a better buy in the short-term than TGTX.

Price Growth

CLLS (@Biotechnology) experienced а -7.69% price change this week, while TGTX (@Biotechnology) price change was -2.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

CLLS is expected to report earnings on May 07, 2025.

TGTX is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TGTX($6.18B) has a higher market cap than CLLS($168M). TGTX YTD gains are higher at: 30.698 vs. CLLS (-33.333). TGTX has higher annual earnings (EBITDA): 49.9M vs. CLLS (-9.46M). TGTX has more cash in the bank: 311M vs. CLLS (260M). CLLS has less debt than TGTX: CLLS (91.5M) vs TGTX (254M). TGTX has higher revenues than CLLS: TGTX (329M) vs CLLS (41.5M).
CLLSTGTXCLLS / TGTX
Capitalization168M6.18B3%
EBITDA-9.46M49.9M-19%
Gain YTD-33.33330.698-109%
P/E RatioN/A262.27-
Revenue41.5M329M13%
Total Cash260M311M84%
Total Debt91.5M254M36%
FUNDAMENTALS RATINGS
CLLS vs TGTX: Fundamental Ratings
CLLS
TGTX
OUTLOOK RATING
1..100
173
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
93
Overvalued
PROFIT vs RISK RATING
1..100
10053
SMR RATING
1..100
9761
PRICE GROWTH RATING
1..100
8535
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLLS's Valuation (23) in the Biotechnology industry is significantly better than the same rating for TGTX (93). This means that CLLS’s stock grew significantly faster than TGTX’s over the last 12 months.

TGTX's Profit vs Risk Rating (53) in the Biotechnology industry is somewhat better than the same rating for CLLS (100). This means that TGTX’s stock grew somewhat faster than CLLS’s over the last 12 months.

TGTX's SMR Rating (61) in the Biotechnology industry is somewhat better than the same rating for CLLS (97). This means that TGTX’s stock grew somewhat faster than CLLS’s over the last 12 months.

TGTX's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for CLLS (85). This means that TGTX’s stock grew somewhat faster than CLLS’s over the last 12 months.

TGTX's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for CLLS (100). This means that TGTX’s stock grew significantly faster than CLLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLLSTGTX
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 19 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GIDCX7.20N/A
N/A
Goldman Sachs Intl Eq Div & Prem C
FDETX23.60N/A
N/A
Fidelity Advisor Capital Development O
SCPAX10.22N/A
N/A
SEI Large Cap Disciplined Eq A (SIIT)
SLLAX12.07N/A
N/A
SEI Small Cap F (SIMT)
MLGLX9.25N/A
N/A
Gabelli Media Mogul A

CLLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLLS has been closely correlated with CMVLF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLLS jumps, then CMVLF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLLS
1D Price
Change %
CLLS100%
-4.76%
CMVLF - CLLS
82%
Closely correlated
N/A
ABCZF - CLLS
58%
Loosely correlated
N/A
SLN - CLLS
43%
Loosely correlated
-5.19%
MDGL - CLLS
40%
Loosely correlated
-2.24%
PMVP - CLLS
38%
Loosely correlated
-0.50%
More